GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Vancomycin oral capsules (Vancocin)

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug2 sources available - open source summaries, references and comparisons

Vancocin

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

VANCOCIN oral capsules - local intestinal treatment and renal cautions

Product / population
Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.
Renal measure
No renal-function dose bands specified for this summary.

Dosing / renal protocol and limits

Adult C. difficile-associated diarrhea: 125 mg orally four times daily for 10 days. Adult staphylococcal enterocolitis: 500 mg-2 g/day in 3-4 divided oral doses for 7-10 days.

These oral capsules do not treat systemic infections; an IV vancomycin regimen must not be substituted.

The label supplies no CrCl-based oral adjustment table. Significant systemic absorption can occur with active colitis, especially with renal insufficiency; serum-level monitoring may sometimes be appropriate. Nephrotoxicity has occurred with oral treatment. Monitor renal function, particularly during and after therapy in patients older than 65 years.

Source revision: DailyMed updated 2025-12-22; prescribing information revised 2025-10 | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a078d9c2-f89c-4f9f-8ded-60ffb2983c3f

Scope: Locally included source-specific summary. Regimen differences are not automatically resolved. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Official product label

VANCOCIN oral capsules - local intestinal treatment and renal cautions

Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.

Renal method: No renal-function dose bands specified for this summary.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Professional guidance

UCSF - oral vancomycin for C. difficile

Adults; oral vancomycin for C. difficile only.

Renal method: Qualitative no renal reduction for these oral regimens.
Retrieved: 2026-09-05

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeVANCOCIN oral capsules - local intestinal treatment and renal cautionsUCSF - oral vancomycin for C. difficile
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a078d9c2-f89c-4f9f-8ded-60ffb2983c3f

Product and population scope

Adult Vancomycin oral capsules (Vancocin). Use only the product, route, indication and renal-replacement setting explicitly stated in the source protocol selected below. Sources are alternatives to compare, not ingredients of a blended regimen.

SCOPE-vancomycin-oral · Source section: Editorial scope; each clinical recommendation is separately attributed belowRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

VANCOCIN oral capsules - local intestinal treatment and renal cautions

Open original reference

Open / share this exact local source

NIH/NLM DailyMed - U.S. product labeling · Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.

Renal method: No renal-function dose bands specified for this summary.
Source date: DailyMed updated 2025-12-22; prescribing information revised 2025-10
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Adult C. difficile-associated diarrhea: 125 mg orally four times daily for 10 days. Adult staphylococcal enterocolitis: 500 mg-2 g/day in 3-4 divided oral doses for 7-10 days.

These oral capsules do not treat systemic infections; an IV vancomycin regimen must not be substituted.

The label supplies no CrCl-based oral adjustment table. Significant systemic absorption can occur with active colitis, especially with renal insufficiency; serum-level monitoring may sometimes be appropriate. Nephrotoxicity has occurred with oral treatment. Monitor renal function, particularly during and after therapy in patients older than 65 years.

RDM30-093-vancomycin-oral-1 · Source locator: VANCOCIN oral capsules - local intestinal treatment and renal cautions; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a078d9c2-f89c-4f9f-8ded-60ffb2983c3f
Retrieved
2026-09-05
DailyMed Set ID
a078d9c2-f89c-4f9f-8ded-60ffb2983c3f
Renal-function method
No renal-function dose bands specified for this summary.
Source date/version
DailyMed updated 2025-12-22; prescribing information revised 2025-10
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
24ff387973db49cc150a0ca7a9e34308353c96b493a4b0278496a232af7a5b3c
Separate professional-source layer

University and professional protocols

Professional

UCSF - oral vancomycin for C. difficile

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adults; oral vancomycin for C. difficile only.

Renal method: Qualitative no renal reduction for these oral regimens.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Initial non-fulminant C. difficile infection: 125 mg orally four times daily. Fulminant disease: 500 mg four times daily under the full severe-CDI pathway; rectal administration may also be considered. The source does not reduce these oral doses for kidney dysfunction or HD.

Oral vancomycin is not a substitute for IV therapy of systemic infection. Taper schedules and additional fulminant-disease treatments require the complete CDI guideline.

RDM30-058-vancomycin-oral-1 · Source locator: UCSF - oral vancomycin for C. difficile; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/vancomycin-po
Retrieved
2026-09-05
Renal-function method
Qualitative no renal reduction for these oral regimens.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
edefb97465d62659caf8025b538583f6ff69af12e65b8d45337c2aeb7e306445

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 0 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a078d9c2-f89c-4f9f-8ded-60ffb2983c3f
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
ec1c1ad7d4f1814f55e036486493eb7b41b914c51ade4dfd36b41f8263409368
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report